Pricing Log in Create free account
Saturday 17 October 2026 Export AVTR’s income statement to Excel — free account

Avantor, Inc.

AVTR Healthcare Medical Instruments & Supplies

Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 33.3%, free cash flow grew 12.7% and total debt fell 12.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

16.42 0.33 +2.05%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
25.5×
Dividend yield
—
F-score
4/9
Altman Z
1.55
Beneish M
−2.91
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 7.56
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 1 — 2 1 — 2 — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 3.05%

Capital & Financial Ratios $m

Market Cap 10,880.00
Revenue 6,561.10
Net Income (578.00)
Free Cash Flow 454.70
Net Debt 3,391.00
Current Ratio 1.78 (at or above 1.5: strong)
Debt/Equity 0.66
P/E ratio 0.00
Fwd P/E 25.50
P/S ratio 1.69
P/B ratio 1.97
Past 5Y EPS Growth —
This Y EPS Growth (9.68%) (below 0%: weak)
Next Y EPS Growth 8.23%
Next Y revenue growth 0.64%
Next 5Y EPS Growth 2.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.2×, against a ten-year median of 2.8×; over the ten years it ranged from 1.3× in 2026 to 4.3× in 2021.
P/S against its own 10 years 34.88%
10-year low 10-year high
P/B against its own 10 years 22.45%
10-year low 10-year high
EV/Sales against its own 10 years 31.12%
10-year low 10-year high
EV/FCF against its own 10 years 79.25%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2027 Powerpack
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 263 262 365 307
Receivables 1,150 1,035 1,075 1,139
Inventory 828 732 818 829
Other 144 119 193 188
2,385 2,147 2,451 2,462
2023 2024 2025 Q'26
Payables 626 663 742 743
ST’ Debt 260 821 31 37
Other 544 475 559 556
1,480 2,008 1,379 1,382

Compound Annual Growth %

10y 5y 3y
Sales — 0.49% (4.46%)
Cash Flow — (7.67%) (9.57%)
Earnings — 0.00% 0.00%
Book Value — 15.78% 4.65%

Revenue $m

Mar Jun Sep Dec Year
’26 1,581 1,692 — — —
’25 1,581 1,683 1,624 1,664 6,552
’24 1,680 1,703 1,714 1,687 6,784
’23 1,780 1,744 1,720 1,723 6,967
’22 1,950 1,911 1,857 1,795 7,512
’21 1,786 1,859 1,834 1,908 7,386
’20 1,519 1,479 1,605 1,791 6,394
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 59 178 — — —
’25 109 154 207 153 624
’24 142 281 245 173 841
’23 220 168 231 252 870
’22 152 228 258 206 844
’21 127 264 262 301 954
’20 253 89 282 306 930
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 25 141 — — —
’25 81 125 172 117 495
’24 107 235 204 146 692
’23 192 138 193 201 724
’22 128 191 219 172 710
’21 112 240 229 261 843
’20 241 76 266 286 868
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.06 0.06 — — —
’25 0.09 0.09 (1.04) 0.08 (0.78)
’24 0.09 0.14 0.08 0.73 1.04
’23 0.18 (0.01) 0.16 0.15 0.47
’22 0.28 0.28 0.25 0.21 1.01
’21 0.25 0.24 0.24 0.13 0.85
’20 0.05 0.08 (0.10) 0.06 0.09
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 13.33 6.66 26.14 17.91 16.63 19.59 10.62

Analyst estimates 2026–2028

Powerpack
High — — — 19.59 28.98 44.37 41.99 25.25 28.00 23.32
People
People Employees — — 12,000 12,000 12,400 13,500 14,500 14,500 13,500 13,500
Revenue/emp, $m 0.00 0.00 0.49 0.50 0.52 0.55 0.52 0.48 0.50 0.49
Income, $m
Income, $m Revenue 691 1,247 5,864 6,040 6,394 7,386 7,512 6,967 6,784 6,552
Gross margin, % 46.31 34.70 31.03 31.80 32.54 33.88 34.65 33.93 33.60 32.65
EBT (71) (460) (114) 41 62 753 851 411 854 (441)
EBT margin, % (10.27) (36.89) (1.94) 0.67 0.97 10.19 11.33 5.89 12.59 (6.74)
Net income (42) (145) (87) 38 117 573 687 321 712 (530)
Depreciation 60 111 446 432 419 396 421 415 417 419
Per share, $
Per share, $ Revenue 1.29 8.26 44.19 15.06 11.09 12.51 11.54 10.31 9.98 9.63
Earnings (0.08) (0.96) (0.65) (0.84) 0.09 0.86 1.02 0.48 1.05 (0.78)
Cash flow 0.14 (1.11) 1.51 0.88 1.61 1.61 1.30 1.29 1.24 0.92
Capex 0.00 (0.17) (0.28) (0.13) (0.11) (0.19) (0.20) (0.22) (0.22) (0.19)
Free cash flow 0.14 (1.28) 1.23 0.75 1.51 1.43 1.09 1.07 1.02 0.73
Book value (0.70) 0.00 (23.00) 6.14 4.64 7.11 7.46 7.77 8.77 8.18
Shares, m 534 151 133 401 576 591 651 676 680 681
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 312.78 49.00 20.55 47.40 20.07 0.00
P/S 0.00 0.00 0.00 1.21 2.54 3.37 1.83 2.21 2.11 1.19
P/B 0.00 0.00 0.00 4.99 9.71 7.79 2.84 2.93 2.40 1.40
EV/Sales 0.00 0.00 0.00 2.02 3.26 4.28 2.62 2.96 2.67 1.74
EV/FCF 38.45 38.45 38.45 40.38 23.99 37.51 27.73 28.53 26.18 22.99
Cash, $m
Cash, $m Operating cash flow 73 (167) 201 354 930 954 844 870 841 624
Capex (30) (25) (38) (52) (62) (111) (133) (146) (149) (129)
Free cash flow 73 (193) 163 302 868 843 710 724 692 495
Balance, $m
Balance, $m Working capital 156 730 803 947 988 1,026 999 905 139 1,072
Total debt 1,296 7,118 6,925 5,117 4,894 7,023 6,288 5,537 4,056 3,946
Net debt 1,233 6,933 6,740 4,930 4,607 6,722 5,915 5,274 3,794 3,581
Shareholders’ equity (375) — (3,052) 2,462 2,674 4,197 4,855 5,253 5,957 5,565
Returns, %
Returns, % ROA (0.73) (19.84) (6.45) (3.40) 0.53 4.27 4.84 2.43 5.67 (4.44)
ROIC 0.00 (1.90) 7.01 4.67 6.07 5.57 6.56 4.13 6.95 (1.68)
ROE 2.80 7.53 12.57 42.07 3.32 20.89 16.46 6.35 12.69 (9.20)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Avantor, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SOLV Solventum Corporation $15.0B 10.4× 39.0× +2.22% (above 0%: growing) +1.92% (above 0%: growing) +144.07% (above 0%: growing) 58.22% 8.19% Compare
BAX Baxter International Inc. $13.3B — (loss-making) 44.7× +5.34% (above 0%: growing) +33.33% (above 0%: growing) +119.48% (above 0%: growing) 34.86% 7.33% Compare
RGEN Repligen Corporation $11.7B 234× 112× +11.93% (above 0%: growing) −65.38% (below 0%: shrinking) +27.10% (above 0%: growing) 53.91% 6.85% Compare
COO The Cooper Companies, Inc. $10.9B 19.8× 28.7× +0.56% (above 0%: growing) +357.14% (above 0%: growing) +65.96% (above 0%: growing) 66.77% 20.82% Compare
AVTR Avantor, Inc. $10.9B — (loss-making) 25.5× +0.53% (above 0%: growing) −33.33% (below 0%: shrinking) +12.66% (above 0%: growing) 31.73% 7.20%
ALGN Align Technology, Inc. $10.6B 25.6× 20.7× +4.32% (above 0%: growing) −12.21% (below 0%: shrinking) +85.77% (above 0%: growing) 71.71% 14.58% Compare
ATR AptarGroup, Inc. $7.9B 22.2× 21.0× +6.26% (above 0%: growing) −18.34% (below 0%: shrinking) −23.07% (below 0%: shrinking) 35.61% 12.34% Compare
BLCO Bausch + Lomb Corporation $6.0B — (loss-making) — (loss-making) +9.08% (above 0%: growing) n/m +251.85% (above 0%: growing) 62.20% 5.95% Compare
TFX Teleflex Incorporated $5.4B — (loss-making) 45.3× +28.88% (above 0%: growing) −17.33% (below 0%: shrinking) +220.14% (above 0%: growing) 58.16% 12.77% Compare
Median of peers $10.8B 22.2× 39.0× +5.80% −12.21% +102.63% 58.19% 10.26%

All 55 Medical Instruments & Supplies stocks →

Avantor, Inc. (AVTR) key facts

  • Concern: Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024.
  • Avantor, Inc. (AVTR) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, AVTR traded at $16.42, a market capitalization of $10.9 billion.
  • Return on equity was −9.20% and debt-to-equity 0.66.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.55 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Avantor, Inc. (AVTR) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/AVTR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com